Diplomat Pharmacy Inc

Diplomat Pharmacy — Q1 2019 Earnings Presentation

14 slides from Diplomat Pharmacy's earnings presentation, May 7, 2019

  1. Slide 1: Disclaimers

    Disclaimers 2 NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuring and impa

  2. Slide 2: Opening Remarks

    Opening Remarks Brian Griffin, Chairman and CEO

  3. Slide 3: 1Q 2019 Highlights

    $1.3B (-6%) Revenue $23M (-42%) Adjusted EBITDA1 • • • • • • • • • Strong growth in infusion Benefit of brand inflation 6 additional LDDs added in the quarter Impact of generics Payer reimbursement compression Volume deterioration in certain therapy classes PBM contract losses & pricing concessions

  4. Slide 4: Putting Patients First

    Putting Patients First 5 Specialty Pharmacy Solutions PBM Manufacturer Services Infrastructure Innovation Infusion Employees JACQUE DIPLOMAT PATIENT

  5. Slide 5: Financial Results

    Financial Results Dan Davison, CFO

  6. Slide 6: 1Q 2019 Financial Results Summary

    1Q 2019 Financial Results Summary 7 Revenue: $1.3B Adjusted EBITDA1: $40M GAAP Net Loss: ($0.5M) GAAP EPS: ($0.01) Revenue: $1.3B Adjusted EBITDA1: $23M GAAP Net Loss: ($14M) GAAP EPS: ($0.19) 1Q18 1Q19 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss), as prepared in

  7. Slide 7: 1Q 2019 Segment Details

    1Q 2019 Segment Details 8 Specialty PBM Revenue: $1.2B Gross margin: 5.8% Rx volume: 225,000 Net Sales/Rx: $5,184 Gross profit/Rx: $298 Revenue: $100M Gross margin: 11.9% Rx volume*: 1,045,000 Gross profit/Rx: $11 * Adjusted to 30-day equivalent, where a 90-day prescription is counted as three 30-da

  8. Slide 8: Revised 2019 Full-Year Outlook

    Revised 2019 Full-Year Outlook 9 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss), as prepared in accordance with GAAP can be found in the Appendix to this presentation. $4.4B–$4.6B $300M–$400M $4.7B–$5.0B Specialty Revenue PBM Revenue Total Revenue Total Adjusted EBI

  9. Slide 9: 2019 Key Headwinds and Tailwinds

    2019 Key Headwinds and Tailwinds 10 Headwinds Payer Reimbursement Pressure Narrowing of Specialty Pharmacy Networks Specialty Pharmacy Member Channel Management PBM Contract Losses PBM Contract Renewal Repricing Moderating Brand Inflation Near-Term Cost of Growth Investments Tailwinds New Specialty

  10. Slide 10: Appendix: Supplemental Financial Information

    Appendix Supplemental Financial Information

  11. Slide 11: Reconciliation of Net (loss) income to Adjusted EBITDA

    For the three months ended March 31, 2019 2018 (dollars in thousands) (unaudited) Net (loss) Depreciation Amortization Interest expense Income tax expense (benefit) EBITDA $ (14,301) 1,684 19,711 10,215 619 $ (450) 1,526 22,425 10,427 (868) $ 17,928 $ 33,060 Contingent consideration and other merger

  12. Slide 12: Revised 2019 Full-Year Outlook: GAAP to Non-GAAP Reconciliation

    Reconciliation of GAAP to Adjusted EBITDA (dollars in thousands) (unaudited) Range Low High Net (loss) Depreciation and amortization Interest expense Income tax (benefit) expense EBITDA $ (49,282) 80,000 40,000 2,582 $ (33,182) 78,000 37,000 1,582 $ 73,300 $ 83,400 Contingent consideration and other

  13. Slide 13: Supplemental Information: Net Debt

    As of March 31, As of December 31, 2019 (dollars in thousands) (unaudited) 2018 Current Liabilities Borrowings on line of credit Current portion of long-term debt Contingent consideration Long-term debt, less current portion Contingent consideration Unamortized debt issuance cost Cash Net Debt 156,5

  14. Slide 14: Supplemental Information: Net Debt

    Supplemental Information: Net Debt Current Liabilities Borrowings on line of credit 156,500 176,300 Current portion of long-term debt 11,500 11,500 Contingent consideration 5,225 5,075 Long-term debt, less current portion 436,187 438,369 Contingent consideration 1,880 1820 Unamortized debt issuance

Diplomat Pharmacy — Q1 2019 Earnings Presentation on 6ix